Accueil » Brèves » Valbiotis announces the positive results of its clinical study on the bioavailability and mode of action of TOTUM•070,against hypercholesterolemia.
The briefing
29Mar2022
Valbiotis announces the positive results of its clinical study on the bioavailability and mode of action of TOTUM•070,against hypercholesterolemia.
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
